Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 8/20 | 0.37 |
| ▸ | GLP1R | P43220 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517453 | 0.80 | MAPT (0.41) | GCGR | |
| SCHEMBL950808 | 0.74 | GCGR (0.33) | GCGRGLP1R | |
| SCHEMBL4443509 | 0.72 | GCGR (0.45) | GCGRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL953439 | 0.70 | GCGR (0.47) | GCGRGLP1RSLC6A4PTPN1PSEN1 | |
| SCHEMBL951189 | 0.69 | GCGR (0.46) | GCGRGLP1R | |
| SCHEMBL950735 | 0.69 | GCGR (0.42) | GCGRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4229216 | 0.62 | GCGR (0.47) | GCGRMMP2MMP9 | |
| SCHEMBL4223386 | 0.62 | GCGR (0.45) | GCGR | |
| SCHEMBL4502610 | 0.61 | MAPT (0.40) | GCGR | |
| SCHEMBL950810 | 0.61 | ALDH1A1 (0.56) | GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009440-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | MARSHALL HOWARD ROBERT | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009440-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SLC18A2, SLC1A2, SLC1A1 | GCGR 604/4885GLP1R 909/4885SLC6A4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.